- Report
- March 2025
- 270 Pages
Global
From €4282EUR$4,799USD£3,776GBP
- Report
- October 2025
- 193 Pages
Global
From €3163EUR$3,545USD£2,789GBP
€3515EUR$3,939USD£3,099GBP
- Report
- August 2025
- 194 Pages
China, Global
From €3163EUR$3,545USD£2,789GBP
€3515EUR$3,939USD£3,099GBP
- Report
- November 2025
- 193 Pages
Global
From €5220EUR$5,850USD£4,603GBP
- Report
- February 2025
- 200 Pages
Global
From €4006EUR$4,490USD£3,533GBP
- Report
- November 2025
- 225 Pages
Global
From €5220EUR$5,850USD£4,603GBP
- Report
- February 2025
- 182 Pages
Global
From €4015EUR$4,500USD£3,540GBP
- Report
- March 2023
- 182 Pages
Global
From €1694EUR$1,899USD£1,494GBP
- Report
- February 2022
- 421 Pages
Global
From €4282EUR$4,799USD£3,776GBP
- Report
- April 2024
- 185 Pages
Global
From €4015EUR$4,500USD£3,540GBP
Bioavailability Enhancement is a process used in pharmaceutical manufacturing to improve the absorption of a drug into the body. This is done by altering the drug's physical or chemical properties, such as its solubility, dissolution rate, or permeability. This can be achieved through various techniques, such as particle size reduction, salt formation, and prodrug design. Bioavailability Enhancement can improve the efficacy of a drug, reduce its side effects, and increase its shelf life.
Companies in the Bioavailability Enhancement market include BASF, Merck, Pfizer, Novartis, and GlaxoSmithKline. Show Less Read more
